|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography 1 1 This study was performed without additional financial support.显示文摘 | Stephen Schroeder Andreas F Kopp Andreas Baumbach Christoph Meisner Axel Kuettner Christian Georg Bernd Ohnesorge Christian Herdeg Claus D Claussen Karl R Karsch | 2001 | Journal of the American College of Cardiology2001，，5： | 3 |
| 2 | Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn’s disease显示文摘AIM: To investigate overlapping regions of the rpoB gene previously involved with rifamycin resistance in M. tuberculosis and seek correlation between rpoB mutations in clinical MAP strains with susceptibility to RIF and RFB. METHODS: We designed a molecular-based PCR method for the evaluation of rifabutin (RFB) and rifampicin (RIF) resistance based on probable determinant regions within the rpoB gene of MAP, including the 81 bp variable site located between nucleotides 1363 and 1443. The minimum inhibitory concentration (MIC) for RIF was also determined against 11 MAP isolates in attempt to seek correlation with rpoB sequences. RESULTS: We determined that MAP strain 18 had an MIC of > 30 mg/L and ≤ 5 mg/L for RIF and RFB respectively, and a significant and novel rpoB mutation C1367T, compared to an MIC of ≤ 1.0 mg/L for both drugs in the wild type MAP. The 30-fold increase in the MIC was a direct result of the rpoB mutation C1367T, which caused an amino acid change Thr456 to Ile456 in the drug’s binding site. In addition, MAP strain 185 contained five silent rpoB mutations and exhibited an MIC comparable to the wild-type. Moreover, our in vitroselected mutation in MAP strain UCF5 resulted in the generation of a new resistant strain (UCF5-RIF16r) that possessed T1442C rpoB mutation and an MIC > 30 mg/L and > 10 mg/L for RIF and RFB respectively. Sequencing of the entire rpoB gene in MAP strains UCF4, 18, and UCF5-RIF16r revealed an rpoB mutation A2284C further downstream of the 81 bp variable region in UCF4, accounting for observed slight increase in MIC. In addition, no other significant mutations were found in strains 18 and UCF-RIF16r. CONCLUSION: The data clearly illustrates that clinical and in vitro-selected MAP mutants with rpoB mutations result in resistance to RIF and RFB, and that a single amino acid change in the beta subunit may have a significant impact on RIF resistance. Unconventional drug susceptibility testing such as our molecular approach will be beneficial for evaluation of antibiotic effectiveness. This molecular approach may also serve as a model for other drugs used for treatment of MAP infections. | Daniel R Beckler Sammer Elwasila George Ghobrial John F Valentine Saleh A Naser | 2008 | World Journal of Gastroenterology2008，14，17： | 2 |
| 3 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 4 | Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘 | Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros | 2009 | The Lancet2009，，9669： | 2 |
| 5 | Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study显示文摘 | Olivier Rixe Ronald M Bukowski M Dror Michaelson George Wilding Gary R Hudes Oliver Bolte Robert J Motzer Paul Bycott Katherine F Liau James Freddo Peter C Trask Sinil Kim Brian I Rini | 2007 | Lancet Oncology2007，，： | 2 |
| 6 | Glutathione Peroxidase 4 Senses and Translates Oxidative Stress into 12/15-Lipoxygenase Dependent- and AIF-Mediated Cell Death显示文摘 | Alexander Seiler Manuela Schneider Heidi F?rster Stephan Roth Eva K. Wirth Carsten Culmsee Nikolaus Plesnila Elisabeth Kremmer Olof R?dmark Wolfgang Wurst Georg W. Bornkamm Ulrich Schweizer Marcus Conrad | 2008 | Cell Metabolism2008，，3： | 2 |
| 7 | Jet cooled NO2 intra cavity laser absorption spectroscopy (ICLAS) between 11 200 and 16 150 cm^-1 显示文摘 | Georges R Delon A Byficki F | 1995 | Chem Phys1995，190，： | 1 |
| 8 | Development of an oral administration of oxytetracycline to control losses due to withering syndrome in cultured red abalone Haliotis rufescens 显示文摘 | CAROLYN S F GEORGE T THEA T R | 2003 | Aquaculture2003，224，： | 1 |
| 9 | RUSLE Revised universal soil loss equation 显示文摘 | KENNETH G R GEORGE R F GLENN A W | 1991 | Journal of soil and water conservation1991，46，： | 1 |
| 10 | RUSLE-Revised universal soil loss equation显示文摘 | Kenneth G R George R F | 1991 | Journal of Soil and Water Conservation1991，46，1： | 1 |
| 11 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial显示文摘 | George L Bakris Pantelis A Sarafidis Matthew R Weir Bj?rn Dahl?f Bertram Pitt Kenneth Jamerson Eric J Velazquez Linda Staikos-Byrne Roxzana Y Kelly Victor Shi Yann-Tong Chiang Michael A Weber | 2010 | The Lancet2010，，9721： | 1 |
| 12 | Logistics planning under uncertainty for disposition of radioactive wastes 显示文摘 | List George F Wood Bryan Turnquist Mark A Nozick Linda K Jones Dean A Lawton Craig R | 2006 | Computers and Operations Research2006，33，3： | 1 |
| 13 | Dendritic cell subset ratio in tolerant,weaning and non-tolerant liver recipients is not affected by extent of immunosuppression显示文摘 | George V Alan F Jorge R | 2005 | Am J Transplant2005，5，： | 1 |
| 14 | The DNA polymerase and helicase genes of a baeulovirus of Orgyia pseudotsugata 显示文摘 | Christian H A George F R | 1996 | Virology1996，77，： | 1 |
| 15 | Geochemical comparison of oil-bearing fluid inelusions and produced oil from the Toro sandstone, Papua New Guinea 显示文摘 | George S C Keieger F W Eadington P J Quezada R A | 1997 | Organic Geochemistry1997，26，： | 1 |
| 16 | Aircraft structural morphing using tendon-actuated compliant cellular trusses显示文摘 | Deepak S R George A L Mary F | 2005 | Journal of Aircraft2005，42，6： | 1 |
| 17 | Unravelling the roles of the apelin system;prospective therapeutic applications in heart failure and obesity显示文摘 | Lee D K George S R O'Dowd B F | 2006 | Trends Pharmacol Sci2006，27，4： | 1 |
| 18 | Determination of the visco - metric constants for chitosan 显示文摘 | George A F R Julan G D | 1992 | Int J Bio Macromol1992，，4： | 1 |
| 19 | Linear stochastic analysis of polluted insulator leakage current 显示文摘 | Amarh F George G Karady Sundararajan R | 2002 | IEEE Transactions on Power Delivery2002，17，4： | 1 |
| 20 | Antigenic and genetic char- acteristics of swine - origin 2009 A( H1N1 ) influenza viruses cir- culating in humans 显示文摘 | Garten R J Davis C T Russell C A Shu B Lindstrom S Balish A Sessions W M Xu X Skepner E Deyde V Okomo - Adhi- ambo M Gubareva L Barnes J Smith C B Emery S L Hillman M J Rivailler P Smagala J de Graaf M Burke D F Fouchier R A Pappas E Alpuche - Aranda C M Lopez - Gatell H Ohvera H Lopez I Myers C A Faix D Blair P J Yu C Keene K M Dotson P D Jr Boxrud D Sambol A R Abid S H St George K Bannerman T Moore A L Stringer D J Blevins P Demmler - Harrison G J Ginsberg M Kriner P Waterman S Smole S Guevara H F Belongia E A Clark P A Beatrice S T Donis R Katz J Finelli L Bridges C B Shaw M Jernigan D B Uyeki T M Smith D J Klimov A I Cox N J | 2009 | Science2009，325，5937： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员